|
|
|
|
November 16, 2024 -Saturday |
|
|
|
 |
| |
|
|
MOU SIGNING CEREMONY BETWEEN CLINICAL RESEARCH MALAYSIA (CRM) AND FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS (FIND)
Friday 03/08/2018
Members of the media are cordially invited to attend the MoU Signing Ceremony between Clinical Research Malaysia (CRM) and Foundation for Innovative New Diagnostics (FIND).
Details of the event are as follows:
Day/Date: Monday 6 August 2018
Time: 10:00 am – 11:00 am
Venue: Pulse Grande Hotel, Precinct 1, Dewan Putra Perdana 1, Level 1, Putrajaya
VIPs:
YB Dr. Dzulkefly Ahmad (Minister of Health, Malaysia)
YBhg. Datuk Dr. Noor Hisham Abdullah (Director-General of Health, Ministry of Health Malaysia)
YBhg. Datuk Dr. Shahnaz Murad (Deputy Director-General of Health (Research & Technical Support),
Ministry of Health Malaysia)
YBhg. Dato' Dr. Goh Pik Pin (Director, National Clinical Research Centre)
Dr. Akhmal Yusof (Chief Executive Officer, Clinical Research Malaysia)
Mr Zachary Katz (Chief Access Officer, FIND)
Programme
9:00 am : Arrival of guests
10:00 am : Arrival of Minister of Health; Ceremony starts
10:05 am : Remarks by Mr Zachary Katz, Chief Access Officer, FIND
10:15 am : Remarks by YB Dr. Dzulkefly Ahmad, Minister of Health, Malaysia
10:25 am : MoU Signing Ceremony
10:35 am : Press Conference
10:55 am : Adjourn for refreshments
About MoU
Foundation for Innovative New Diagnostics (FIND) and Clinical Research Malaysia (CRM) sign Memorandum of Understanding to work together to simplify and decentralise hepatitis C virus (HCV) screening and treatment
Initiative conducted in partnership with the Drugs for Neglected Diseases initiative (DNDi) and in collaboration with the Ministry of Health in Malaysia, underscoring the government’s world-leading efforts to tackle the disease
About hepatitis C
HCV is one of the world’s most common infectious diseases, usually contracted through unsafe healthcare and injection drug use. Globally, more than 71 million people are chronically infected, over 80% of whom live in low- and middle-income countries (LMICs) – but only one in five people know they have the disease. Around 400,000 people die every year, and the mortality rate is increasing, making it a global health priority: the World Health Organization (WHO) has set an ambitious target of viral hepatitis elimination by 2030. , In Malaysia, HCV disease burden is high and predicted to rise steeply over the coming decades, leading to a projected 63,900 HCV-related deaths by 2039.
About Clinical Research Malaysia (CRM)
Established by the Malaysian Ministry of Health in 2012, CRM exists to advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to- end clinical research support for quality studies. CRM’s innate understanding of the local clinical research landscape with the international standards of operations coupled with fundamental backing of the government ministries provide us an incomparable advantage to work with partners from the nascent stages of development to materialisation of the end product, in order to deliver better treatment and high skilled job opportunities. For further information, please visit www.clinicalresearch.my
About FIND
FIND was established in 2003 as a global non-profit dedicated to accelerating the development, evaluation and delivery of high-quality, affordable diagnostic tests for poverty-related diseases, now including malaria, tuberculosis, HIV/AIDS, sleeping sickness, hepatitis C, leishmaniasis, Chagas disease, Buruli ulcer, non-malarial fever and diseases with outbreak potential, such as Ebola. FIND has partnered in the delivery of 20 new diagnostic tools and created an enabling environment for numerous others through the provision of specimen banks, reagent development and better market visibility. FIND also supports better access to new diagnostics through implementation, quality assurance and lab strengthening work. FIND has nearly 200 partners globally, including research institutes and laboratories, health ministries and national disease control programmes, commercial partners, bilateral and multilateral organizations, especially WHO, and clinical trial sites. For further information, please visit www.finddx.org
[1] World Health Organization. Global hepatitis report 2017. www.who.int/hepatitis/publications/
global-hepatitis-report2017/en/ (accessed 27 June 2018)
[2] World Health Organization. Disease burden and mortality estimates, 2000–2015.
http://www.who.int/healthinfo/global_burden_disease/estimates/en/index1.html (accessed 27 June 2018)
[3] World Health Organization. Combating hepatitis B and C to reach elimination by 2030, May 2016. http://apps.who.int/iris/bitstream/handle/10665/206453/WHO_HIV_2016.04_eng.pdf;jsessionid=
0B0881916BBDF9EB2B47D4B004DB7969?sequence=1 (accessed 5 July 2018)
[4] Raihan R, et al. Euroasian J Hepato-Gastroenterol 2017;7(1):65–67
You are cordially invited to send a reporter and photographer/cameraman to cover the Signing Ceremony.
Source: Clinical Research Malaysia (CRM)
FOR MORE INFORMATION AND RSVP, PLEASE CONTACT:
Name: Syed Hamzah Syed Noordin
Tel: +603 7960 5153 (ext. 121)
Email: hamzah@clinicalresearch.my
Website: http://www.clinicalresearch.my
-BERNAMA
|
|
|
|
|
|
